secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001493152-23-024400
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q2 2023 preliminary revenue $5.7M-$5.9M, up 26%-31% YoY; reaffirms FY growth 25%
--------------------------------------------------------------------------------

- Q2 2023 preliminary revenue range $5.7M-$5.9M, a 26%-31% increase over Q2 2022.
- H1 2023 revenue estimated at $14.4M-$14.6M, reflecting 1%-3% growth YoY.
- Full-year 2023 revenue growth reaffirmed at least 25% over 2022.
- Management cites increasing adoption of photodynamic therapy and larger contract wins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/0001493152-23-024400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315223024400/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer